EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer

Background Pancreatic ductal adenocarcinoma (PDAC) frequently resists conventional cytotoxic therapy. The antitumor effects of endothelial monocyte-activating polypeptide II (EMAP) have been attributed to its antiendothelial and antiangiogenic activities. We tested the hypothesis that a combination...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2010-05, Vol.17 (5), p.1442-1452
Hauptverfasser:	Schwarz, Roderich E., Awasthi, Niranjan, Konduri, Srivani, Cafasso, Danielle, Schwarz, Margaret A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis - drug effects Bevacizumab Blotting, Western Carcinoma, Pancreatic Ductal - blood supply Carcinoma, Pancreatic Ductal - pathology Cell Proliferation - drug effects Cytokines - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Female Immunoenzyme Techniques Medicine Medicine & Public Health Mice Mice, Nude Neoplasm Proteins - administration & dosage Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Oncology Pancreatic cancer Pancreatic Neoplasms - blood supply Pancreatic Neoplasms - pathology Platelet Endothelial Cell Adhesion Molecule-1 - metabolism RNA-Binding Proteins - administration & dosage Surgery Surgical Oncology Survival Rate Translational Research and Biomarkers Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!